Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma …

L Catley, E Weisberg, T Kiziltepe, YT Tai, T Hideshima… - Blood, 2006 - ashpublications.org
L Catley, E Weisberg, T Kiziltepe, YT Tai, T Hideshima, P Neri, P Tassone, P Atadja
Blood, 2006ashpublications.org
Histone deacetylase (HDAC) inhibitors have shown cytotoxicity as single agents in
preclinical studies for multiple myeloma (MM) cells. LBH589 is a novel hydroxamic acid
derivative that at low nanomolar concentrations induces apoptosis in MM cells resistant to
conventional therapies via caspase activation and poly-(ADP-ribose) polymerase (PARP)
cleavage. Significant synergistic cytotoxicity was observed with LBH589 in combination with
bortezomib against MM cells that were sensitive and resistant to dexamethasone (Dex), as …
Abstract
Histone deacetylase (HDAC) inhibitors have shown cytotoxicity as single agents in preclinical studies for multiple myeloma (MM) cells. LBH589 is a novel hydroxamic acid derivative that at low nanomolar concentrations induces apoptosis in MM cells resistant to conventional therapies via caspase activation and poly-(ADP-ribose) polymerase (PARP) cleavage. Significant synergistic cytotoxicity was observed with LBH589 in combination with bortezomib against MM cells that were sensitive and resistant to dexamethasone (Dex), as well as primary patient MM cells. LBH589 at low nanomolar concentrations also induced α-tubulin hyperacetylation. Aggresome formation was observed in the presence of bortezomib, and the combination of LBH589 plus bortezomib induced the formation of abnormal bundles of hyeracetylated α-tubulin but with diminished aggresome size and apoptotic nuclei. These data confirm the potential clinical benefit of combining HDAC inhibitors with proteasome inhibitors, and provide insight into the mechanisms of synergistic anti-MM activity of bortezomib in combination with LBH589.
ashpublications.org